[
  {
    "ts": "2026-01-14T19:05:56+00:00",
    "headline": "JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries",
    "summary": "The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.",
    "url": "https://www.pharmaceutical-technology.com/news/jpm26-regeneron-will-not-overpay-in-ma-deals-amid-lead-asset-patent-expiries/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "375e4db9-6181-3821-9bcb-4290020235b0",
      "content": {
        "id": "375e4db9-6181-3821-9bcb-4290020235b0",
        "contentType": "STORY",
        "title": "JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries",
        "description": "",
        "summary": "The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.",
        "pubDate": "2026-01-14T19:05:56Z",
        "displayTime": "2026-01-14T19:05:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/dcf209ea892e803958fbc3cccb3050d7",
          "originalWidth": 883,
          "originalHeight": 589,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VFlbyMvvq8ElHARcb9DQJg--~B/aD01ODk7dz04ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/dcf209ea892e803958fbc3cccb3050d7.cf.webp",
              "width": 883,
              "height": 589,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FIToxu2r2zojgF8v6k3sZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/dcf209ea892e803958fbc3cccb3050d7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/jpm26-regeneron-will-not-overpay-in-ma-deals-amid-lead-asset-patent-expiries/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-regeneron-not-overpay-m-190556340.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]